Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
McKesson
Colorcon
Johnson and Johnson
Medtronic

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Raltitrexed

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Raltitrexed?

Raltitrexed is an investigational drug.

There have been 36 clinical trials for Raltitrexed. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Neoplasm Metastasis, and Carcinoma. The leading clinical trial sponsors are Fudan University, National Cancer Institute (NCI), and Hospira, Inc.

There is one US patent protecting this investigational drug and nineteen international patents.

Recent Clinical Trials for Raltitrexed
TitleSponsorPhase
Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell CarcinomaNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegePhase 2
Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell CarcinomaBeijing Konruns Pharmaceutical Co., Ltd.Phase 2
Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With ThrombocytopeniaFudan UniversityPhase 2

See all Raltitrexed clinical trials

Clinical Trial Summary for Raltitrexed

Top disease conditions for Raltitrexed
Top clinical trial sponsors for Raltitrexed

See all Raltitrexed clinical trials

US Patents for Raltitrexed

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Raltitrexed   Start Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Start Trial
Raltitrexed   Start Trial Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Raltitrexed   Start Trial Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same Duquesne University of the Holy Spirit (Pittsburgh, PA)   Start Trial
Raltitrexed   Start Trial Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Raltitrexed

Drugname Country Document Number Estimated Expiration Related US Patent
Raltitrexed World Intellectual Property Organization (WIPO) 2015148714 2034-03-25   Start Trial
Raltitrexed Australia 2015231053 2034-03-21   Start Trial
Raltitrexed Brazil 112016021620 2034-03-21   Start Trial
Raltitrexed Canada 2943339 2034-03-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Moodys
McKinsey
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.